Novartis Ag (NVSEF) Revenue (QoQ) (2009 - 2023)
Novartis Ag (NVSEF) Revenue (QoQ) (2009 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 3,429.94% |
| Mar 31, 2023 | 27.56% |
| Dec 31, 2022 | 7.63% |
| Sep 30, 2022 | -98.15% |
| Jun 30, 2022 | 4,873.15% |
| Mar 31, 2022 | -98.99% |
| Dec 31, 2021 | 11,124.34% |
| Sep 30, 2021 | -98.26% |
| Jun 30, 2021 | 4,510.68% |
| Mar 31, 2021 | 16.12% |
| Dec 31, 2020 | 1.68% |
| Sep 30, 2020 | -97.90% |
| Jun 30, 2020 | 4,647.70% |
| Jun 30, 2019 | 4,905.96% |
| Mar 31, 2019 | 3.07% |
| Dec 31, 2018 | -10.59% |
| Sep 30, 2018 | -98.06% |
| Jun 30, 2018 | 6,106.60% |
| Mar 31, 2018 | 4.95% |
| Dec 31, 2017 | 5.21% |